Skip to content
DataLookout
Menu

Dexmed/tapNCT06624319

Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
  2. Minor Study title shortened, about 1 wordv2
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Total morphine consumption during the first 24 hours postoperatively
Timeframe: First 24 hours postoperative

Secondary (2)

Severity of pain using Visual analogue scale
Patient level of sedation using four point modified ramsy scale

Arms and interventions

tap block with 0.5 μg/kg dexmedetomidineActive comparator

will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

tap block with 1.5 μg/kg dexmedetomidineActive comparator

will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Drugs: Dexmedetomidine as adjuvent to bupvacaine in tap block

Sites

1 site in 1 country

  • South egypt cancer institute,Assiut UniversityAsyut, Egypt